MannKind Corporation (MNKD) is a diverse biopharmaceutical company committed to revolutionizing the therapeutic market with their cutting-edge, technosphere-based drug delivery platform. Founded in February 1991 and headquartered in Westlake Village, California, MannKind's mission is to deliver state-of-the-art treatments with minimal impact on daily life. The company's innovation and ingenuity have positioned them to contribute unique solutions that address the unmet needs in the medical community.
Their groundbreaking inhalable insulin medication, Afrezza, reflects this commitment. Afrezza is a rapid-acting, inhaled insulin designed to control high blood sugar in adults who have type 1 or type 2 diabetes. Noted for its unique method of delivery, which bypasses the traditional needle injection, the medication is touted for its convenience and ease-of-use, offering substantial benefit to those struggling with the everyday management of diabetes.
Led by President and CEO Michael Castagna, PharmD, MannKind Corporation continues to work tirelessly in the pursuit of life-changing medical advancements. Their robust pipeline includes several promising inhalable therapeutics, including treprostinil for pulmonary arterial hypertension and epoprostenol for pulmonary hypertension, among others.
Throughout their operational history, MannKind Corporation has demonstrated a knack for innovation, something they have been acknowledged for within the industry. Despite initial setbacks such as the rejection of Afrezza by FDA in 2011, the company's relentless pursuit of research and development has propelled it forward. In 2014, MNKD received much-awaited FDA approval for Afrezza, a testament to their resilience and persistence.
Financially, MannKind Corp has faced its fair share of ups and downs. The innovative firm has struggled with profitability, forcing them to seek partnerships and collaborations for additional funding. Notable partnerships include United Therapeutics Corporation, which had licensed the rights to treprostinil.
As MannKind Corporation moves forward, they continue to broaden their horizon, exploring other applications for their technosphere technology outside of diabetes and pulmonary hypertension, hoping to continue making strides in multiple therapeutic areas. Despite market challenges and tight competition, MNKD's focus on innovation and patient-centered approach sets them apart. As they pioneer forward, the global healthcare industry watches on with keen interest.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
MannKind Corporation shares are trading lower after announcing a licensing and collaboration agreement with Rose Pharma. The partnership focuses on developing an inhaled, rapid-acting GLP-1 receptor agonist for weight management, combining Rose Pharma's molecule with MannKind's Technosphere inhalation technology. MannKind will receive an equity interest and potential royalties, supporting the development through Phase 1b.
MannKind (MNKD) stock is considered 48% undervalued with a fair value estimated at $7.59 per share, significantly higher than its recent $3.95 close. This valuation is based on the projected growth of Afrezza through international expansion and a broadened salesforce, coupled with the progress of its late-stage pipeline programs for respiratory diseases. Despite recent underperformance, the company's future revenue growth and potential for expanded product offerings support the undervalued narrative, though risks like Afrezza's limited market adoption persist.
MannKind Corporation (NASDAQ: MNKD) has submitted a prospectus supplement to its automatic shelf registration statement, which includes a legal opinion from Cooley LLP validating the legality of its common stock issuance and sale. This filing was made with the SEC on August 21, 2026, and confirms that MannKind's common stock is traded on NASDAQ. The report also clarifies that MannKind does not qualify as an emerging growth company.